CTLA4 and neoplasm: In a different study using the MOC1 tumor model, depletion of G-MDSCs with a Ly6G+ mAb in combination with anti-CTLA4 led to tumor rejection in 11/11 mice, whereas anti-CTLA4 treatment led to tumor rejection in 5/11 mice [59], providing further evidence for the efficacy of strategies that target MDSCs to improve immunotherapy responses.